Antiangiogenic therapies in endometriosis

Keyphrases

• Endometriosis 100%
• Antiangiogenic Therapy 100%
• Clinical Trials 50%
• Progestin 50%
• Gonadotropin-releasing Hormone 50%
• Oral Contraceptives 50%
• Blood Vessels 50%
• Rapamycin 50%
• Angiostatic 50%
• Anti-vascular Endothelial Growth Factor (anti-VEGF) 50%
• Endometrial Lesions 50%
• Androgenic Agents 50%
• Anginex 50%
• Endostatin 50%
• New Options 50%
• Angiogenesis Inhibitors 50%
• Endometriosis Treatment 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Endometriosis 100%
• Antiangiogenic Therapy 100%
• Diseases 66%
• Clinical Trial 33%
• Progestin 33%
• Angiogenesis Inhibitor 33%
• Vasculotropin 33%
• Rapamycin 33%
• Androgen 33%
• Gonadorelin Derivative 33%
• Oral Contraceptive 33%
• Anginex 33%
• Fumagillol Chloroacetylcarbamate 33%
• Endostatin 33%

Veterinary Science and Veterinary Medicine

• Endometriosis 100%
• Diseases 66%
• Androgen 33%
• Vascular Endothelial Growth Factor 33%
• Progestin 33%
• Gonadotropin-Releasing Hormone Analogue 33%